Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 13NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 5Classical hematology 5Myeloid 4Lymphoid 2Sarcoma 1Plasma cell 1

Conditions

Sarcoma 317Gastrointestinal Stromal Tumors 108Neoplasms 105Breast Neoplasms 92Melanoma 81Ovarian Neoplasms 79Neoplasm Metastasis 74Carcinoma, Non-Small-Cell Lung 74Colorectal Neoplasms 70Osteosarcoma 61Stomach Neoplasms 59Pancreatic Neoplasms 55Bone Neoplasms 55Prostatic Neoplasms 51Head and Neck Neoplasms 48Glioblastoma 48Sarcoma, Ewing 47Lung Neoplasms 45Esophageal Neoplasms 42Squamous Cell Carcinoma of Head and Neck 41Carcinoma, Renal Cell 40Uterine Cervical Neoplasms 39Sarcoma, Kaposi 38Lymphoma 37Urinary Bladder Neoplasms 36Sarcoma, Synovial 36Recurrence 35Dendritic Cell Sarcoma, Interdigitating 34Lymphoma, Non-Hodgkin 33Endometrial Neoplasms 33

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Anemia, Refractory × Sarcoma × Clear all
NCT00891137 2014-10-27

Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy

Cellerant Therapeutics

Phase 1 Completed
30 enrolled
Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cellSarcoma

Congenital Abnormalities, Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Blast Crisis, Burkitt Lymphoma, Leukemia, Lymphoma, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Multiple Myeloma, Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms, Plasma Cell, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡